Grail shares climbed 55 percent through Friday morning after a Food and Drug Administration advisory panel voted to recommend the company's Galleri multi-cancer early detection test, clearing a critical regulatory hurdle that could unlock broader insurance coverage and clinical adoption.
The vote breakdown
The Molecular and Clinical Genetics Devices Panel voted unanimously on safety, seven to two that benefits outweigh risks, and six to four on effectiveness. The narrow efficacy margin reflects the central tension in the data: Galleri failed to hit its primary endpoint in a three-year, 142,250-person study run with England's National Health Service, which looked for a statistically meaningful drop in late-stage, Stage III and Stage IV, cancer detection.
The bull case rests on episode sensitivity
Management has consistently pointed to a different metric: episode sensitivity across the 12 deadliest cancers, which account for two-thirds of cancer deaths. The argument is that catching those earlier generates enough treatment-cost savings to offset the expense of the test itself and the follow-up work prompted by false positives. The panel's endorsement strengthens that case with insurers, many of whom have held back pending formal FDA approval.
What comes next
A favorable panel vote does not guarantee premarket approval, though it makes it substantially more likely. If the FDA follows the recommendation, the focus shifts to coverage decisions by Medicare and commercial payers, and whether the cost-effectiveness math holds up outside a trial setting. The 6-to-4 split on efficacy suggests the agency will scrutinize real-world evidence closely before writing a broad label.